WO2014018563A3 - Methods for the treatment of cancer - Google Patents
Methods for the treatment of cancer Download PDFInfo
- Publication number
- WO2014018563A3 WO2014018563A3 PCT/US2013/051737 US2013051737W WO2014018563A3 WO 2014018563 A3 WO2014018563 A3 WO 2014018563A3 US 2013051737 W US2013051737 W US 2013051737W WO 2014018563 A3 WO2014018563 A3 WO 2014018563A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- methods
- cancer
- cancers
- neuroendocrine tumors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Described herein are methods for the treatment of cancers, particularly neuroendocrine tumors. Also described herein are methods for selecting drug candidates for the treatment of cancers such as neuroendocrine tumors.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261674810P | 2012-07-23 | 2012-07-23 | |
US61/674,810 | 2012-07-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014018563A2 WO2014018563A2 (en) | 2014-01-30 |
WO2014018563A3 true WO2014018563A3 (en) | 2014-05-01 |
Family
ID=49997958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/051737 WO2014018563A2 (en) | 2012-07-23 | 2013-07-23 | Methods for the treatment of cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014018563A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110262354A1 (en) | 2007-07-13 | 2011-10-27 | Emory University | Cyanine-containing compounds for cancer imaging and treatment |
US9675620B2 (en) | 2011-07-26 | 2017-06-13 | University Of Southern California | MAO inhibitors and their conjugates as therapeutics for the treatment of brain cancer |
CN106132437A (en) * | 2014-02-07 | 2016-11-16 | 南加州大学 | MAO inhibitor and conjugate thereof as brain cancer treatment therapeutic agent |
WO2016062272A1 (en) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | Applications of immune disease medicament in preparing cancer-inhibiting pharmaceutical composition |
CA2973913C (en) | 2015-01-19 | 2021-12-14 | Belina Pharma Ab | Antihistamine for use in treatment of breast cancer |
WO2016167605A2 (en) * | 2015-04-16 | 2016-10-20 | 서울대학교 산학협력단 | Method for inhibiting lung cancer of smokers and non-smokers using hypertension medicine |
KR101938036B1 (en) * | 2015-04-16 | 2019-01-14 | 서울대학교산학협력단 | Method for inhibiting lung carcinogenesis of both smokers and non-smokers by using antihypertensive drugs |
WO2017177037A1 (en) * | 2016-04-06 | 2017-10-12 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
SG11201809440PA (en) * | 2016-05-02 | 2018-11-29 | T & A Pharma Pty Ltd | Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith |
US20210121475A1 (en) * | 2017-06-20 | 2021-04-29 | The Board Of Regents Of The Universy Of Texas System | Imipramine compositions and methods of treating cancer |
US11357766B2 (en) | 2017-11-13 | 2022-06-14 | Texas Tech University System | Compositions and methods for treating cancer |
US20220118160A1 (en) * | 2018-09-23 | 2022-04-21 | University Of Wollongong | An implantable device and a method for implanting said device in a subject |
US10639315B1 (en) | 2019-05-21 | 2020-05-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating Alzheimer's disease |
US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
US10966989B2 (en) | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
EP3952840A4 (en) * | 2019-04-12 | 2022-11-23 | La Pharma Tech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
CN110755431B (en) * | 2019-11-08 | 2023-02-28 | 暨南大学 | Application of desloratadine in preparation of anti-liver cancer drugs |
EP4203944A1 (en) * | 2020-08-31 | 2023-07-05 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Active agent combination for treatment of cancer |
CN114432446B (en) * | 2020-11-05 | 2023-07-04 | 南湖实验室 | Application of antihistamine in preparation of antitumor drugs |
US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018402A1 (en) * | 1998-09-28 | 2000-04-06 | Merck & Co., Inc. | Method for treating androgen-related conditions |
WO2002036114A1 (en) * | 2000-11-01 | 2002-05-10 | Respiratorius Ab | Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3 |
US20020193371A1 (en) * | 2001-06-01 | 2002-12-19 | Adam Telerman | Drugs which can be used in the treatment of cancer |
WO2003007925A1 (en) * | 2001-07-19 | 2003-01-30 | Isis Innovation Limited | Therapeutic strategies for prevention and treatment of alzheimer's disease |
WO2007006581A2 (en) * | 2005-07-13 | 2007-01-18 | Universitätsklinikum Freiburg | Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression |
WO2007109142A2 (en) * | 2006-03-17 | 2007-09-27 | Oregon Health & Science University | M3 muscarinic receptor antagonists for treating tumors |
US20090005456A1 (en) * | 2007-05-31 | 2009-01-01 | Sepracor Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
WO2011050180A1 (en) * | 2009-10-21 | 2011-04-28 | Immunogen, Inc. | Novel dosing regimen and method of treatment |
WO2012106851A1 (en) * | 2011-02-12 | 2012-08-16 | 安徽三安光电有限公司 | Method of cleaving semiconductor wafer or package substrate |
-
2013
- 2013-07-23 WO PCT/US2013/051737 patent/WO2014018563A2/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018402A1 (en) * | 1998-09-28 | 2000-04-06 | Merck & Co., Inc. | Method for treating androgen-related conditions |
WO2002036114A1 (en) * | 2000-11-01 | 2002-05-10 | Respiratorius Ab | Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3 |
US20020193371A1 (en) * | 2001-06-01 | 2002-12-19 | Adam Telerman | Drugs which can be used in the treatment of cancer |
WO2003007925A1 (en) * | 2001-07-19 | 2003-01-30 | Isis Innovation Limited | Therapeutic strategies for prevention and treatment of alzheimer's disease |
WO2007006581A2 (en) * | 2005-07-13 | 2007-01-18 | Universitätsklinikum Freiburg | Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression |
WO2007109142A2 (en) * | 2006-03-17 | 2007-09-27 | Oregon Health & Science University | M3 muscarinic receptor antagonists for treating tumors |
US20090005456A1 (en) * | 2007-05-31 | 2009-01-01 | Sepracor Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
WO2011050180A1 (en) * | 2009-10-21 | 2011-04-28 | Immunogen, Inc. | Novel dosing regimen and method of treatment |
WO2012106851A1 (en) * | 2011-02-12 | 2012-08-16 | 安徽三安光电有限公司 | Method of cleaving semiconductor wafer or package substrate |
Also Published As
Publication number | Publication date |
---|---|
WO2014018563A2 (en) | 2014-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014018563A3 (en) | Methods for the treatment of cancer | |
HK1222121A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc ( nsclc ) | |
EP3558324A4 (en) | Cyclic dinucleotide sting agonists for cancer treatment | |
IL280565A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
EP3265079A4 (en) | Molecular profiling for cancer | |
EP3092006A4 (en) | Targeted therapy for small cell lung cancer | |
EP3033079A4 (en) | Methods for the treatment of her2 amplified cancer | |
EP3027192A4 (en) | Methods for the treatment of solid tumors | |
EP4276200A3 (en) | Fgfr-tacc fusion proteins and methods thereof | |
EP3052933A4 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
PH12014502032A1 (en) | Treatment of brain cancer | |
EP3383407A4 (en) | Cytarabine conjugates for cancer therapy | |
EP3736022A3 (en) | Treatment and diagnosis of colon cancer | |
WO2013106747A3 (en) | Methods and compositions for the treatment and diagnosis of thyroid cancer | |
EP3347098A4 (en) | Targeting mda-5 activation for cancer immunotherapy | |
EP3589732A4 (en) | Detecting prostate cancer | |
WO2013188750A3 (en) | Substituted macrocyclic compounds having proteasome inhibitory activity | |
EP3089745A4 (en) | Compounds, compositions, and methods for the treatment of cancers | |
EP3332037A4 (en) | Methods for predicting prostate cancer relapse | |
WO2013070933A3 (en) | Compositions and methods for the treatment of prostate carcinoma | |
WO2014079931A8 (en) | Cd44v6-derived peptides for treating breast cancers | |
GB201313987D0 (en) | Novel immunotherapy against several tumors, such as lung cancer including NSCLC | |
GB201403297D0 (en) | Novel immunotherapy against several tumors, such as lung cancer, including NSCLC |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13823823 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13823823 Country of ref document: EP Kind code of ref document: A2 |